{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:16Z","timestamp":1786980136373,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T00:00:00Z","timestamp":1531094400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00415-018-8959-8","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T05:14:33Z","timestamp":1531113273000},"page":"2114-2119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Low specificity of voltage-gated calcium channel antibodies in Lambert\u2013Eaton myasthenic syndrome: a call for caution"],"prefix":"10.1007","volume":"265","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4963-0719","authenticated-orcid":false,"given":"Rodica","family":"Di Lorenzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Mente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luay","family":"Shayya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Rae-Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adham","family":"Jammoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,9]]},"reference":[{"key":"8959_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","volume":"332","author":"VA Lennon","year":"1995","unstructured":"Lennon VA, Kryzer TJ, Griesmann GE et al (1995) Calcium-channel antibodies in the Lambert\u2013Eaton syndrome and other paraneoplastic syndromes. NEJM 332:1467\u20131474. \n                    https:\/\/doi.org\/10.1056\/NEJM199506013322203","journal-title":"NEJM"},{"key":"8959_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","volume":"147","author":"M Motomura","year":"1997","unstructured":"Motomura M, Lang B, Johnston I et al (1997) Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert\u2013Eaton myasthenic syndrome. J Neurol Sci 147:35\u201342. \n                    https:\/\/doi.org\/10.1016\/S0022-510X(96)05303-8","journal-title":"J Neurol Sci"},{"key":"8959_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/0166-2236(89)90109-4","volume":"12","author":"A Vincent","year":"1989","unstructured":"Vincent A, Lang B, Newsom-Davis J (1989) Autoimmunity to the voltage-gated calcium channel underlies the Lambert\u2013Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci 12:496\u2013502","journal-title":"Trends Neurosci"},{"key":"8959_CR4","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Lang B, Verschuuren JJ (2011) Lambert\u2013Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 10:1098\u20131107","journal-title":"Lancet Neurol"},{"key":"8959_CR5","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA (1989) 3,4-Diaminopyridine in the treatment of Lambert\u2013Eaton myasthenic syndrome. N Engl J Med 321:1567\u20131571. \n                    https:\/\/doi.org\/10.1056\/NEJM198912073212303","journal-title":"N Engl J Med"},{"key":"8959_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/mus.21422","volume":"40","author":"SJ Oh","year":"2009","unstructured":"Oh SJ, Claussen GG, Hatanaka Y, Morgan MB (2009) 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 40:795\u2013800. \n                    https:\/\/doi.org\/10.1002\/mus.21422","journal-title":"Muscle Nerve"},{"key":"8959_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/WNL.54.3.603","volume":"54","author":"DB Sanders","year":"2000","unstructured":"Sanders DB, Massey JM, Sanders LL, Edwards LJ (2000) A randomized trial of 3,4-diaminopyridine in Lambert\u2013Eaton myasthenic syndrome. Neurology 54:603\u2013607","journal-title":"Neurology"},{"key":"8959_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/clpt.2009.35","volume":"86","author":"PW Wirtz","year":"2009","unstructured":"Wirtz PW, Verschuuren JJ, Van Dijk JG et al (2009) Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert\u2013Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 86:44\u201348. \n                    https:\/\/doi.org\/10.1038\/clpt.2009.35","journal-title":"Clin Pharmacol Ther"},{"key":"8959_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/mus.25070","volume":"53","author":"SJ Oh","year":"2016","unstructured":"Oh SJ, Shcherbakova N, Kostera-Pruszczyk A et al (2016) Amifampridine phosphate (Firdapse\u00ae) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve 53:717\u2013725. \n                    https:\/\/doi.org\/10.1002\/mus.25070","journal-title":"Muscle Nerve"},{"key":"8959_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/mus.26052","volume":"57","author":"DB Sanders","year":"2018","unstructured":"Sanders DB, Juel VC, Harati Y et al (2018) 3,4-Diaminopyridine base effectively treats the weakness of Lambert\u2013Eaton myasthenia. Muscle Nerve 57:561\u2013568. \n                    https:\/\/doi.org\/10.1002\/mus.26052","journal-title":"Muscle Nerve"},{"key":"8959_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/mus.25009","volume":"53","author":"TM Burns","year":"2016","unstructured":"Burns TM, Smith GA, Allen JA et al (2016) Editorial by concerned physicians: unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve 53:165\u2013168","journal-title":"Muscle Nerve"},{"key":"8959_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0140-6736(81)90474-8","volume":"318","author":"B Lang","year":"1981","unstructured":"Lang B, Wray D, Newsom-Davis J et al (1981) Autoimmune aetiology for myasthenic (Eaton\u2013Lambert) syndrome. Lancet 318:224\u2013226. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(81)90474-8","journal-title":"Lancet"},{"key":"8959_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","volume":"58","author":"M Motomura","year":"1995","unstructured":"Motomura M, Johnston I, Lang B et al (1995) An improved diagnostic assay for Lambert\u2013Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 58:85\u201387","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8959_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1212\/01.WNL.0000037485.56217.5F","volume":"59","author":"YK Nakao","year":"2002","unstructured":"Nakao YK, Motomura M, Fukudome T et al (2002) Seronegative Lambert\u2013Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59:1773\u20131775","journal-title":"Neurology"},{"key":"8959_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/mus.25027","volume":"54","author":"NL Zalewski","year":"2016","unstructured":"Zalewski NL, Lennon VA, Lachance DH et al (2016) P\/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments. Muscle Nerve 54:220\u2013227. \n                    https:\/\/doi.org\/10.1002\/mus.25027","journal-title":"Muscle Nerve"},{"key":"8959_CR16","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1007\/s00415-017-8627-4","volume":"264","author":"H Abboud","year":"2017","unstructured":"Abboud H, Rossman I, Mealy MA et al (2017) Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results. J Neurol 264:2284\u20132292. \n                    https:\/\/doi.org\/10.1007\/s00415-017-8627-4","journal-title":"J Neurol"},{"key":"8959_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/00207454.2016.1207644","volume":"127","author":"R Albadareen","year":"2017","unstructured":"Albadareen R, Gronseth G, Goeden M et al (2017) Paraneoplastic autoantibody panels: sensitivity and specificity, a retrospective cohort. Int J Neurosci 127:531\u2013538. \n                    https:\/\/doi.org\/10.1080\/00207454.2016.1207644","journal-title":"Int J Neurosci"},{"key":"8959_CR18","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00415-017-8541-9","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Eymard B, Datt J, Mantegazza R (2017) Lambert\u2013Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol 264:1854\u20131863","journal-title":"J Neurol"},{"key":"8959_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mus.24559","volume":"52","author":"Y Li","year":"2015","unstructured":"Li Y, Jammoul A, Mente K et al (2015) Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center. Muscle Nerve 52:386\u2013391. \n                    https:\/\/doi.org\/10.1002\/mus.24559","journal-title":"Muscle Nerve"},{"key":"8959_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1212\/CPJ.0000000000000268","volume":"6","author":"A Jammoul","year":"2016","unstructured":"Jammoul A, Shayya L, Mente K et al (2016) Clinical utility of seropositive voltage-gated potassium channel-complex antibody. Neurol Clin Pract 6:409\u2013418. \n                    https:\/\/doi.org\/10.1212\/CPJ.0000000000000268","journal-title":"Neurol Clin Pract"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-8959-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8959-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-8959-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T19:11:05Z","timestamp":1562613065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-8959-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,9]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["8959"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-8959-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,9]]},"assertion":[{"value":"3 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Ethical standards concerning safeguarging patients\u2019 protected health information, in addition to compliance with the Institutional Review Board were strictly adhered to.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}